|
1
|
Martin-Giacalone BA, Weinstein PA, Plon SE
and Lupo PJ: Pediatric rhabdomyosarcoma: Epidemiology and genetic
susceptibility. J Clin Med. 10:20282021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McEvoy MT, Siegel DA, Dai S, Okcu MF,
Zobeck M, Venkatramani R and Lupo PJ: Pediatric rhabdomyosarcoma
incidence and survival in the United States: An assessment of 5656
cases, 2001-2017. Cancer Med. 12:3644–3656. 2023. View Article : Google Scholar :
|
|
3
|
Oberlin O, Rey A, Lyden E, Bisogno G,
Stevens MCG, Meyer WH, Carli M and Anderson JR: Prognostic factors
in metastatic rhabdomyosarcomas: Results of a pooled analysis from
United States and European cooperative groups. J Clin Oncol.
26:2384–2389. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weigel BJ, Lyden E, Anderson JR, Meyer WH,
Parham DM, Rodeberg DA, Michalski JM, Hawkins DS and Arndt CA:
Intensive multiagent therapy, including dose-compressed cycles of
ifosfamide/etoposide and vincristine/doxorubicin/cyclophosphamide,
irinotecan, and radiation, in patients with high-risk
rhabdomyosarcoma: A report from the children's oncology group. J
Clin Oncol. 34:117–122. 2016. View Article : Google Scholar :
|
|
5
|
Clark KL, Halay ED, Lai E and Burley SK:
Co-crystal structure of the HNF-3/fork head DNA-recognition motif
resembles histone H5. Nature. 364:412–420. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kalin TV, Ustiyan V and Kalinichenko VV:
Multiple faces of FoxM1 transcription factor: Lessons from
transgenic mouse models. Cell Cycle. 10:396–405. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Milewski D, Balli D, Ustiyan V, Le T,
Dienemann H, Warth A, Breuhahn K, Whitsett JA, Kalinichenko VV and
Kalin TV: FOXM1 activates AGR2 and causes progression of lung
adenomas into invasive mucinous adenocarcinomas. PLoS Genet.
13:e10070972017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Weiler SME, Pinna F, Wolf T, Lutz T,
Geldiyev A, Sticht C, Knaub M, Thomann S, Bissinger M, Wan S, et
al: Induction of chromosome instability by activation of
yes-associated protein and forkhead box M1 in liver cancer.
Gastroenterology. 152:2037–2051.e22. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheng XH, Black M, Ustiyan V, Le T,
Fulford L, Sridharan A, Medvedovic M, Kalinichenko VV, Whitsett JA
and Kalin TV: SPDEF inhibits prostate carcinogenesis by disrupting
a positive feedback loop in regulation of the Foxm1 oncogene. PLoS
Genet. 10:e10046562014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang IC, Ustiyan V, Zhang Y, Cai Y, Kalin
TV and Kalinichenko VV: Foxm1 transcription factor is required for
the initiation of lung tumorigenesis by oncogenic Kras(G12D.).
Oncogene. 33:5391–5396. 2014. View Article : Google Scholar
|
|
11
|
Cai Y, Balli D, Ustiyan V, Fulford L,
Hiller A, Misetic V, Zhang Y, Paluch AM, Waltz SE, Kasper S and
Kalin TV: Foxm1 expression in prostate epithelial cells is
essential for prostate carcinogenesis. J Biol Chem.
288:22527–22541. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Balli D, Ren X, Chou FS, Cross E, Zhang Y,
Kalinichenko VV and Kalin TV: Foxm1 transcription factor is
required for macrophage migration during lung inflammation and
tumor formation. Oncogene. 31:3875–3888. 2012. View Article : Google Scholar
|
|
13
|
Li L, Wu D, Yu Q, Li L and Wu P:
Prognostic value of FOXM1 in solid tumors: A systematic review and
meta-analysis. Oncotarget. 8:32298–32308. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kuda M, Kohashi K, Yamada Y, Maekawa A,
Kinoshita Y, Nakatsura T, Iwamoto Y, Taguchi T and Oda Y: FOXM1
expression in rhabdomyosarcoma: A novel prognostic factor and
therapeutic target. Tumour Biol. 37:5213–5223. 2016. View Article : Google Scholar
|
|
15
|
Nestal de Moraes G, Bella L, Zona S,
Burton MJ and Lam EWF: Insights into a critical role of the
FOXO3a-FOXM1 axis in DNA damage response and genotoxic drug
resistance. Curr Drug Targets. 17:164–177. 2016. View Article : Google Scholar
|
|
16
|
Merjaneh N, Hajjar M, Lan YW, Kalinichenko
VV and Kalin TV: The promise of combination therapies with FOXM1
inhibitors for cancer treatment. Cancers (Basel). 16:7562024.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ustiyan V, Zhang Y, Perl AKT, Whitsett JA,
Kalin TV and Kalinichenko VV: β-catenin and Kras/Foxm1 signaling
pathway are critical to restrict Sox9 in basal cells during
pulmonary branching morphogenesis. Dev Dyn. 245:590–604. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun L, Ren X, Wang IC, Pradhan A, Zhang Y,
Flood HM, Han B, Whitsett JA, Kalin TV and Kalinichenko VV: The
FOXM1 inhibitor RCM-1 suppresses goblet cell metaplasia and
prevents IL-13 and STAT6 signaling in allergen-exposed mice. Sci
Signal. 10:eaai85832017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shukla S, Milewski D, Pradhan A, Rama N,
Rice K, Le T, Flick MJ, Vaz S, Zhao X, Setchell KD, et al: The
FOXM1 inhibitor RCM-1 decreases carcinogenesis and nuclear
β-catenin. Mol Cancer Ther. 18:1217–1229. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Donovan J, Deng Z, Bian F, Shukla S,
Gomez-Arroyo J, Shi D, Kalinichenko VV and Kalin TV: Improving
anti-tumor efficacy of low-dose vincristine in rhabdomyosarcoma via
the combination therapy with FOXM1 inhibitor RCM1. Front Oncol.
13:11128592023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fairlie WD and Lee EF: Targeting the
BCL-2-regulated apoptotic pathway for the treatment of solid
cancers. Biochem Soc Trans. 49:2397–2410. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Steinert DM, Salganick J, Ballo M, Zhang
W, Munsell M, Raney B, Jaffe N, Koh J, El-Naggar A and Trent J:
Expression of Bax and Bcl-2 in human rhabdomyosarcoma: Correlation
with survival in 64 patients. J Clin Oncol. 23(Suppl 16):
S90412005. View Article : Google Scholar
|
|
23
|
Armistead PM, Salganick J, Roh JS,
Steinert DM, Patel S, Munsell M, El-Naggar AK, Benjamin RS, Zhang W
and Trent JC: Expression of receptor tyrosine kinases and apoptotic
molecules in rhabdomyosarcoma: Correlation with overall survival in
105 patients. Cancer. 110:2293–2303. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ploumaki I, Triantafyllou E,
Koumprentziotis IA, Karampinos K, Drougkas K, Karavolias I,
Trontzas I and Kotteas EA: Bcl-2 pathway inhibition in solid
tumors: A review of clinical trials. Clin Transl Oncol.
25:1554–1578. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Heinicke U, Haydn T, Kehr S, Vogler M and
Fulda S: BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma
cells to histone deacetylase inhibitor-induced apoptosis. Oncogene.
37:5325–5339. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Alcon C, Manzano-Muñoz A, Prada E, Mora J,
Soriano A, Guillén G, Gallego S, Roma J, Samitier J, Villanueva A
and Montero J: Sequential combinations of chemotherapeutic agents
with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance.
Cell Death Dis. 11:6342020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Alcon C, Martín F, Prada E, Mora J,
Soriano A, Guillén G, Gallego S, Roma J, Samitier J, Villanueva A
and Montero J: MEK and MCL-1 sequential inhibition synergize to
enhance rhabdomyosarcoma treatment. Cell Death Discov. 8:1722022.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Goldsmith KC, Verschuur A, Morgenstern DA,
van Eijkelenburg N, Federico SM, Fraser C, Forlenza CJ, Ziegler DS,
Gerber NU, Khaw AL, et al: The first report of pediatric patients
with solid tumors treated with venetoclax. J Clin Oncol. 38(15
Suppl): S105242020. View Article : Google Scholar
|
|
29
|
Hinson ARP, Jones R, Crose LES, Belyea BC,
Barr FG and Linardic CM: Human rhabdomyosarcoma cell lines for
rhabdomyosarcoma research: Utility and pitfalls. Front Oncol.
3:1832013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Leddon JL, Chen CY, Currier MA, Wang PY,
Jung FA, Denton NL, Cripe KM, Haworth KB, Arnold MA, Gross AC, et
al: Oncolytic HSV virotherapy in murine sarcomas differentially
triggers an antitumor T-cell response in the absence of virus
permissivity. Mol Ther Oncolytics. 1:140102015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Milewski D, Pradhan A, Wang X, Cai Y, Le
T, Turpin B, Kalinichenko VV and Kalin TV: FoxF1 and FoxF2
transcription factors synergistically promote rhabdomyosarcoma
carcinogenesis by repressing transcription of p21Cip1
CDK inhibitor. Oncogene. 36:850–862. 2017. View Article : Google Scholar :
|
|
32
|
Sun F, Wang G, Pradhan A, Xu K,
Gomez-Arroyo J, Zhang Y, Kalin GT, Deng Z, Vagnozzi RJ, He H, et
al: Nanoparticle delivery of STAT3 alleviates pulmonary
hypertension in a mouse model of alveolar capillary dysplasia.
Circulation. 144:539–555. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Deng Z, Lin J, Bud'ko SL, Webster B, Kalin
TV, Kalinichenko VV and Shi D: Dual targeting with cell surface
electrical charge and folic acid via superparamagnetic
Fe3O4@Cu2-xS for photothermal
cancer cell killing. Cancers (Basel). 13:52752021. View Article : Google Scholar
|
|
34
|
Deng Z, Gao W, Kohram F, Li E, Kalin TV,
Shi D and Kalinichenko VV: Fluorinated amphiphilic Poly(β-Amino
ester) nanoparticle for highly efficient and specific delivery of
nucleic acids to the Lung capillary endothelium. Bioact Mater.
31:1–17. 2023.
|
|
35
|
Milewski D, Shukla S, Gryder BE, Pradhan
A, Donovan J, Sudha P, Vallabh S, Pyros A, Xu Y, Barski A, et al:
FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in
rhabdomyosarcoma. Oncogene. 40:2182–2199. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Singh S, Uppuluri P, Mamouei Z, Alqarihi
A, Elhassan H, French S, Lockhart SR, Chiller T, Edwards JE Jr and
Ibrahim AS: The NDV-3A vaccine protects mice from multidrug
resistant Candida auris infection. PLoS Pathog. 15:e10074602019.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li Z, Wang H, Li S, Deng B, Zhang W, Wu P,
Li W, Xin P, Zhao L and Gao S: Anti-pseudomonas aeruginosa activity
of the scorpion-derived peptide GK8. Probiotics Antimicrob
Proteins. Jul 3–2025.Epub ahead of print.
|
|
38
|
Acharya A, Bian F, Gomez-Arroyo J, Wagner
KA, Kalinichenko VV and Kalin TV: Hypoxia represses FOXF1 in lung
endothelial cells through HIF-1α. Front Physiol. 14:13091552024.
View Article : Google Scholar
|
|
39
|
Shukla S, Saha T, Rama N, Acharya A, Le T,
Bian F, Donovan J, Tan LA, Vatner R, Kalinichenko V, et al:
Ultra-high dose-rate proton FLASH improves tumor control. Radiother
Oncol. 186:1097412023. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
41
|
Love MI, Huber W and Anders S: Moderated
estimation of fold change and dispersion for RNA-seq data with
DESeq2. Genome Biol. 15:5502014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Emig D, Salomonis N, Baumbach J, Lengauer
T, Conklin BR and Albrecht M: AltAnalyze and DomainGraph: Analyzing
and visualizing exon expression data. Nucleic Acids Res.
38:W755–W762. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen J, Bardes EE, Aronow BJ and Jegga AG:
ToppGene Suite for gene list enrichment analysis and candidate gene
prioritization. Nucleic Acids Res. 37:W305–W311. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tang D, Chen M, Huang X, Zhang G, Zeng L,
Zhang G, Wu S and Wang Y: SRplot: A free online platform for data
visualization and graphing. PLoS One. 18:e02942362023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
De Micheli AJ, Spector JA, Elemento O and
Cosgrove BD: A reference single-cell transcriptomic atlas of human
skeletal muscle tissue reveals bifurcated muscle stem cell
populations. Skelet Muscle. 10:192020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wei Y, Qin Q, Yan C, Hayes MN, Garcia SP,
Xi H, Do D, Jin AH, Eng TC, McCarthy KM, et al: Single-cell
analysis and functional characterization uncover the stem cell
hierarchies and developmental origins of rhabdomyosarcoma. Nat
Cancer. 3:961–975. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dalton KM, Krytska K, Lochmann TL, Sano R,
Casey C, D'Aulerio A, Khan QA, Crowther GS, Coon C, Cai J, et al:
Venetoclax-based rational combinations are effective in models of
MYCN-amplified neuroblastoma. Mol Cancer Ther. 20:1400–1411. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Curry MC, Luk NA, Kenny PA,
Roberts-Thomson SJ and Monteith GR: Distinct regulation of
cytoplasmic calcium signals and cell death pathways by different
plasma membrane calcium ATPase isoforms in MDA-MB-231 breast cancer
cells. J Biol Chem. 287:28598–28608. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sritangos P, Pena Alarcon E, James AD,
Sultan A, Richardson DA and Bruce JIE: Plasma membrane
Ca2+ ATPase isoform 4 (PMCA4) has an important role in
numerous hallmarks of pancreatic cancer. Cancers (Basel).
12:2182020. View Article : Google Scholar
|
|
50
|
Naffa R, Hegedűs L, Hegedűs T, Tóth S,
Papp B, Tordai A and Enyedi Á: Plasma membrane Ca2+ pump
isoform 4 function in cell migration and cancer metastasis. J
Physiol. 602:1551–1564. 2024. View Article : Google Scholar
|
|
51
|
ENCODE Project Consortium: An integrated
encyclopedia of DNA elements in the human genome. Nature.
489:57–74. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang J, Liu J, Lee D, Lou S, Chen Z,
Gürsoy G and Gerstein M: DiNeR: A differential graphical model for
analysis of co-regulation network rewiring. BMC Bioinformatics.
21:2812020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ruymann FB: The development of VAC
chemotherapy in rhabdomyosarcoma: What does one do for an encore?
Curr Oncol Rep. 5:505–509. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Nguyen TH and Barr FG: Therapeutic
approaches targeting PAX3-FOXO1 and its regulatory and
transcriptional pathways in rhabdomyosarcoma. Molecules.
23:27982018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Chen C, Dorado Garcia H, Scheer M and
Henssen AG: Current and future treatment strategies for
rhabdomyosarcoma. Front Oncol. 9:14582019. View Article : Google Scholar
|
|
56
|
Kalinichenko VV and Kalin TV: Is there
potential to target FOXM1 for 'undruggable' lung cancers? Expert
Opin Ther Targets. 19:865–867. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Black M, Arumugam P, Shukla S, Pradhan A,
Ustiyan V, Milewski D, Kalinichenko VV and Kalin TV: FOXM1 nuclear
transcription factor translocates into mitochondria and inhibits
oxidative phosphorylation. Mol Biol Cell. 31:1411–1424. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Stafford N, Wilson C, Oceandy D, Neyses L
and Cartwright EJ: The plasma membrane calcium ATPases and their
role as major new players in human disease. Physiol Rev.
97:1089–1125. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
James AD, Chan A, Erice O, Siriwardena AK
and Bruce JIE: Glycolytic ATP fuels the plasma membrane calcium
pump critical for pancreatic cancer cell survival. J Biol Chem.
288:36007–36019. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Hegedũs L, Garay T, Molnár E, Varga K,
Bilecz Á, Török S, Padányi R, Pászty K, Wolf M, Grusch M, et al:
The plasma membrane Ca2+ pump PMCA4b inhibits the
migratory and metastatic activity of BRAF mutant melanoma cells.
Int J Cancer. 140:2758–2770. 2017. View Article : Google Scholar
|
|
61
|
Ribiczey P, Tordai A, Andrikovics H,
Filoteo AG, Penniston JT, Enouf J, Enyedi A, Papp B and Kovács T:
Isoform-specific up-regulation of plasma membrane Ca2+ATPase
expression during colon and gastric cancer cell differentiation.
Cell Calcium. 42:590–605. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Aung C, Kruger W, Poronnik P,
Roberts-Thomson S and Monteith G: Plasma membrane Ca2+-ATPase
expression during colon cancer cell line differentiation. Biochem
Biophys Res Commun. 355:932–936. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Sloan CA, Chan ET, Davidson JM, Malladi
VS, Strattan JS, Hitz BC, Gabdank I, Narayanan AK, Ho M, Lee BT, et
al: ENCODE data at the ENCODE portal. Nucleic Acids Res.
44:D726–D732. 2016. View Article : Google Scholar :
|
